Insider Trading November 21, 2026 07:31 AM

Medifast Director Parsa Kiai Discloses $1.13 Million Stock Purchase

The director acquired 94,036 shares over two days as the stock traded near $11.75, down more than 9% in the past week.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
MED

Parsa Kiai, a director at Medifast, purchased 94,036 shares of company stock on November 18 and 19, 2026, for a total of $1,133,816. The transactions were executed at prices ranging from $11.855 to $12.20 per share. Following the purchases, Kiai's indirect beneficial ownership stands at 828,016 shares. The buying occurred as Medifast shares traded at $11.75, down over 9% in the past week. The company recently reported third-quarter 2026 results that exceeded Wall Street expectations, with a smaller-than-expected loss and revenue of $72.05 million.

Medifast Director Parsa Kiai Discloses $1.13 Million Stock Purchase
MED
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Parsa Kiai, a Medifast director, purchased 94,036 shares for $1,133,816 on November 18-19, 2026, at prices from $11.855 to $12.20.
  • The purchases were made as Medifast stock traded at $11.75, down over 9% in the past week.
  • Medifast's third-quarter 2026 results exceeded expectations, with a smaller loss and revenue of $72.05 million.
  • The consumer staples sector and small-cap equities may be impacted by insider activity and earnings surprises.

Medifast Inc. (NYSE:MED) director Parsa Kiai has disclosed a series of open-market purchases of the company's common stock totaling $1,133,816, according to filings covering transactions on November 18 and 19, 2026. The acquisitions, which spanned two trading sessions, involved 94,036 shares and were executed at prices between $11.855 and $12.20 per share.

The buying activity unfolded as Medifast shares changed hands at $11.75, a level that reflects a decline of more than 9% over the past week. The stock's recent pullback provides the backdrop for the director's purchases, which were made at prices slightly above the prevailing market quote.

Transaction Details

On November 18, 2026, Kiai acquired 8,886 shares at an average price of $12.1613, with individual transaction prices ranging from $12.06 to $12.20. The following day, November 19, 2026, he purchased an additional 85,150 shares at an average price of $12.0464, with prices ranging from $11.855 to $12.15.

All reported shares are held indirectly. The ownership is attributed to Steamboat Capital Partners Master Fund, LP, and Steamboat Capital Partners II, LP. Kiai serves as Managing Member of Steamboat Capital Partners GP, LLC, which acts as the general partner for both funds and has delegated investment discretion to Steamboat Capital Partners, LLC. As a result, Kiai may be deemed to have a pecuniary interest in the shares, though he disclaims beneficial ownership except to that extent.

Following these transactions, Kiai's indirect beneficial ownership of Medifast common stock stands at 828,016 shares.

Recent Financial Results

The insider buying comes after Medifast reported third-quarter 2026 financial results that surpassed Wall Street expectations. The company announced a smaller-than-expected loss, with adjusted earnings showing a negative $0.19 per share, while analysts had projected a loss of $0.62 per share. Revenue for the quarter reached $72.05 million, exceeding the forecasted $67.7 million.

These results indicate a positive trajectory in the company's turnaround efforts, and the earnings report was a key highlight for investors, showing that Medifast is performing better than anticipated.

The stock's recent price action and the director's purchases may draw attention from market participants evaluating the company's valuation and prospects. Medifast shares closed at $11.75 on the day of the disclosure, down $0.23 or 1.92%.

Risks

  • The stock's recent decline of over 9% in the past week may continue, affecting investor confidence in the consumer staples sector.
  • Insider purchases may not signal future performance, and the company's turnaround efforts may face uncertainties.
  • The broader market volatility could impact small-cap stocks like Medifast, which operate in the weight-loss and nutrition segment.

More from Insider Trading

York Water Director Brossman Adds 31.971 Shares in Small Open-Market Purchase Nov 21, 2026 Solaris Energy President Ramachandran Buys $159,750 in Stock as Shares Retreat Nov 21, 2026 Legend Biotech CEO Ingrid Zhang Buys $163,200 in Shares Near 52-Week Low Nov 21, 2026 Lipocine Director John Higuchi Purchases $225,225 in Company Stock Nov 20, 2026 Home Depot Chair Decker Offloads $6.55 Million in Shares Following Option Exercise Nov 20, 2026